![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | A61K 31/138 | (2006.01) |
A61K 31/439 | (2006.01) | ||
A61K 45/06 | (2006.01) | ||
A61P 11/06 | (2006.01) | ||
A61P 11/08 | (2006.01) |
(11) | Number of the document | 2506844 |
(13) | Kind of document | T |
(96) | European patent application number | 10781527.6 |
Date of filing the European patent application | 2010-11-29 | |
(97) | Date of publication of the European application | 2012-10-10 |
(45) | Date of publication and mention of the grant of the patent | 2017-12-20 |
(46) | Date of publication of the claims translation | 2018-03-12 |
(86) | Number | PCT/EP2010/068429 |
Date | 2010-11-29 |
(87) | Number | WO 2011/067212 |
Date | 2011-06-09 |
(30) | Number | Date | Country code |
0921075 | 2009-12-01 | GB |
(72) |
BAKER, Darrell, GB
BRUCE, Mark, GB
CRATER, Glenn, US
NOGA, Brian, US
THOMAS, Marian, GB
WIRE, Patrick, US
|
(73) |
Glaxo Group Limited,
980 Great West Road, Brentford, Middlesex TW8 9GS,
GB
|
(74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
(54) | Muskarininio receptoriaus antagonisto ir beta-2 adrenoreceptoriaus agonisto deriniai |
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Payment date | Validity (years) | Amount | |
2024-10-22 | 15 | 289.00 EUR |
2025-11-29 |